Novartis Commits $1.7 Billion to AI-Driven Drug Discovery

Pharmaceutical giant partners with AI biotech Relation Therapeutics to accelerate target discovery for atopic dermatitis and chronic skin diseases.

Key Takeaways

• $1.7 billion partnership sealed: Novartis commits $55 million upfront to Relation Therapeutics, with milestone payments potentially reaching $1.7 billion plus tiered royalties for AI-driven immuno-dermatology drug discovery.
• AI-native platform secures pharma backing: Relation’s Lab-in-the-Loop technology integrates artificial intelligence with multi-omic data to identify causal genes for atopic skin diseases, attracting investments from both Novartis and GSK within months.
• Strategic shift in R&D approach: Novartis moves drug development risk upstream into target discovery by securing global rights to Relation’s discoveries without acquiring the platform outright.

Introduction

Novartis has committed up to $1.7 billion to partner with British biotech Relation Therapeutics in a deal that places artificial intelligence at the center of immuno-dermatology drug discovery. The Swiss pharmaceutical giant provides $55 million upfront through cash, equity investment, and research funding to access Relation’s AI-enabled platform for identifying novel treatment targets in atopic diseases. This collaboration marks a significant strategic shift as large pharmaceutical companies increasingly embed AI technology into early-stage research to reduce development risk and accelerate time to market.

The partnership grants Novartis global development and commercialization rights for any resulting drug candidates. Relation will deploy its Lab-in-the-Loop platform to integrate AI analysis with proprietary experimental systems and multi-omic patient data, aiming to pinpoint causal genes before clinical trials begin.

Key Developments

The collaboration focuses on advancing targets for atopic diseases, a category that includes conditions like atopic dermatitis and chronic allergic skin disorders. Relation will initially conduct observational studies using patient tissue samples to build functional cell atlases of disease states, providing a biological roadmap for drug developers.

Relation Therapeutics was established in early 2024 and quickly secured $60 million in seed funding before attracting a $45 million investment from GSK for separate work on fibrotic diseases and osteoarthritis. The Novartis deal represents the biotech’s largest partnership to date and validates its AI-native approach to target discovery.

Novartis already holds a strong position in dermatology with blockbuster products including Cosentyx for psoriasis and Xolair for chronic hives. The company recently gained approval for Rhapsido, a BTK inhibitor targeting chronic spontaneous urticaria, reinforcing its commitment to expanding its immunology pipeline.

Market Impact

The deal underscores growing investor and industry confidence in AI-driven biology platforms. Relation counts NVentures, the venture arm of chipmaker Nvidia, among its backers, highlighting crossover interest from technology and healthcare sectors in computational drug discovery.

Pharmaceutical companies face mounting pressure to improve R&D productivity amid rising development costs and lengthening timelines. Partnerships with AI-enabled biotechs allow large drugmakers to access cutting-edge technology and shift capital allocation toward later-stage assets with validated targets, reducing early-stage attrition rates.

Novartis demonstrates a strategic preference for platform partnerships over full acquisitions, enabling the company to maintain flexibility while securing preferential access to high-value targets. The structure provides Relation with capital to expand its technology while preserving independence to pursue additional collaborations.

Strategic Insights

The collaboration reflects a broader industry trend of integrating artificial intelligence into upstream drug discovery. Traditional pharmaceutical R&D relies heavily on hypothesis-driven target selection, often leading to high failure rates in clinical trials when biological mechanisms prove more complex than anticipated.

Relation’s platform aims to address this challenge by using AI to analyze large-scale multi-omic datasets—including genomics, transcriptomics, and proteomics—to identify causal disease pathways rather than correlative biomarkers. This approach promises to improve target validation before costly clinical programs begin.

Novartis benefits by embedding AI capabilities into its immuno-dermatology strategy without building the infrastructure internally. The deal also positions the company to capture first-in-class assets in atopic disease, an area with significant unmet medical need and commercial potential.

Expert Opinions and Data

Fiona Marshall, Ph.D., President of Biomedical Research at Novartis, emphasized that AI-driven approaches accelerate drug discovery and enhance the potential to deliver better outcomes for patients. Her remarks signal Novartis’s commitment to making computational biology a core pillar of its research strategy.

David Roblin, CEO of Relation Therapeutics, expressed confidence that the partnership will transform treatment standards for patients suffering from atopic conditions. Roblin’s company has rapidly built credibility in the techbio space, securing major pharmaceutical partnerships within its first year of operation.

The involvement of NVentures as an investor highlights the convergence of computational hardware and biological software. Nvidia’s chips power many AI training workloads, and the company increasingly sees drug discovery as a high-growth application area for its technology.

Conclusion

Novartis’s $1.7 billion commitment to Relation Therapeutics represents a calculated investment in AI-native drug discovery and a strategic move to reinforce leadership in immuno-dermatology. By securing global rights to targets identified through Relation’s platform, Novartis shifts development risk earlier in the pipeline while maintaining capital efficiency.

The partnership illustrates how large pharmaceutical companies now view AI-enabled biotechs as essential collaborators rather than speculative bets. As the industry faces pressure to improve productivity, deals structured around platform access and milestone-based payments offer a pragmatic path to innovation without the complexity of full acquisitions.